Skip to main content
. 2019 May 3;33(3):933–937. doi: 10.21873/invivo.11561

Table II. Clinical activity of napabucasin.

graphic file with name in_vivo-33-935-i0002.jpg

CR: Complete response; OS: overall survival; PFS: progression-free survival; SD: stable disease. One month=30.4375 days. *Patient was censored, neither progressive disease (PD) nor death were observed at the date of the last assessment of objective tumour response.